全身性エリテマトーデス及びループス腎炎：企業と競争環境...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Market Outlook 12
3.1 Global Markets 12
3.1.1 Forecast 12
3.1.2 Drivers and Barriers – Global Issues 19
4 Current and Future Players 22
4.1 Overview 22
4.2 Trends in Corporate Strategy 24
4.3 Company Profiles 26
4.3.1 GlaxoSmithKline 26
4.3.2 Roche 28
4.3.3 UCB 31
4.3.4 Eli Lilly and Company 33
4.3.5 Bristol-Myers Squibb 35
4.3.6 Anthera Pharmaceuticals 36
4.3.7 ImmuPharma 38
4.3.8 Merck Serono 39
5 Appendix 41
5.1 Bibliography 41
5.2 Abbreviations 41
5.3 Methodology 43
5.4 Forecasting Methodology 43
5.4.1 Diagnosed SLE and LN Patients 43
5.4.2 Percent Drug-Treated Patients 44
5.4.3 Drugs Included in Each Therapeutic Class 44
5.4.4 General Pricing Assumptions 44
5.4.5 Generic Erosion 45
5.5 Physicians and Specialists Included in this Study 45
5.6 Primary Research – Prescriber Survey 47
5.7 About the Authors 48
5.7.1 Analysts 48
5.7.2 Global Head of Healthcare 49
5.8 About GlobalData 50
5.9 Disclaimer 50